Recent clinical trials of neoadjuvant treatment and adjuvant treatment for resectable NSCLC have shown that epidermal growth factor receptor-TKI and ICI therapy might provide a superior DFS benefit [11–14]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.